News Headlines

  1. Eurofins CDMO Alphora Announces Development & Implementation Of AI-Powered Salt And Co-Crystal Screening Software 1/26/2026

    Developed by Eurofins CDMO Alphora, in collaboration with a local university, this cutting-edge machine learning platform provides highly accurate predictions of salt and co-crystal formation for APIs and intermediates.

  2. MS Pharma Group Signs Exclusive Biosimilars Partnership Agreement With Hetero 1/26/2026

    MS Pharma Group, a leading regional pharmaceutical company in the MENA region, has signed a strategic partnership agreement with Hetero Group, a global pharmaceutical company, to localize five established biosimilars across key therapeutic areas, including oncology, immunology and hematology.

  3. HanchorBio And WuXi Biologics Enter Strategic Partnership To Advance Next-Generation Bi-And Multi-Functional Fusion Protein Pipeline 1/26/2026

    HanchorBio, Inc., a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, and WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), jointly announced today the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

  4. SpectronRx Accelerates Commercial Growth With Major Expansion Of Its Grissom Aeroplex Manufacturing Campus 1/23/2026

    SpectronRx, a global radiopharmaceutical CDMO, CMO and isotope producer, has announced a major expansion of its Grissom Aeroplex commercial manufacturing campus near Bunker Hill, substantially increasing its capacity to deliver high-volume therapeutic and diagnostic doses to partners worldwide.

  5. Coating Place Announces Leadership Appointments To Support Next Phase Of Growth 1/23/2026

    As Coating Place celebrates its 50th anniversary, the company continues to build on its long-standing reputation as the industry leader in Wurster-based fluid bed technology for controlled release and taste masking applications.

  6. bioMérieux Acquires Accellix To Elevate Pharmaceutical Quality Control And Accelerate Advanced Therapies 1/22/2026

    bioMérieux, a world leader in the field of in vitro diagnostics, announces the acquisition of Accellix, a US company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control.

  7. Janux Therapeutics Announces Collaboration And Exclusive Worldwide License Agreement With Bristol Myers Squibb To Develop A Novel Tumor-Activated Therapeutic For Solid Tumors 1/22/2026

    Janux Therapeutics, Inc. (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced a collaboration and exclusive worldwide license agreement with Bristol Myers Squibb.

  8. Mikart Celebrates 50 Years Of Excellence In Pharmaceutical Manufacturing 1/22/2026

    Mikart, a leading Contract Development and Manufacturing Organization (CDMO) specializing in small-molecule pharmaceutical products, proudly celebrates its 50th anniversary. Since its founding in 1975, Mikart has been dedicated to delivering innovative solutions, quality manufacturing, and outstanding service to its clients in the pharmaceutical industry.

  9. Mikart Signs Lease For New Headquarters At Cumberland Center II In Northwest Atlanta 1/22/2026

    Mikart, a leading contract development and manufacturing organization (CDMO), today announced that it has signed a lease for new headquarters space at the Cumberland Center II, a premier office tower in the Cumberland-Galleria region of Northwest Atlanta. The newly leased facility, encompassing approximately 13,000 square feet, will house Mikart’s administrative and corporate functions.

  10. SK Bioscience, MSD, And Hilleman Laboratories Advance Zaire Ebolavirus Vaccine Development With CEPI Funding 1/22/2026

    SK bioscience announced that it is advancing the development of a Zaire ebolavirus vaccine under a new collaboration supported by the Coalition for Epidemic Preparedness Innovations (CEPI).